Transplant coronary heart disease: challenges and solutions

References

• Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy–2010. J Heart Lung Transplant. 2010;29(7):717–727.
   PubMed Web of Science ®Google Scholar
• Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report–2010. J Heart Lung Transplant. 2010;29:1089–1103.
   PubMed Web of Science ®Google Scholar
• Colvin-Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future direction. Clin Transplant. 2011;25(2):175–184.
   Web of Science ®Google Scholar
• Prada-Delgado O, Estevez-Loureiro R, Paniagua-Martin MJ, Lopez-Sainz A, Crespo-Leiro MG. Prevalence and prognostic value of cardiac allograft vasculopathy 1 year after heart transplantation according to the ISHLT recommended nomenclature. J Heart Lung Transplant. 2012;31:332–333.
   PubMed Web of Science ®Google Scholar
• Zimmer RJ, Lee MS. Transplant coronary artery disease. JACC Cardiovasc Interv. 2010;3:367–377.
   Web of Science ®Google Scholar
• Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report–2012. J Heart Lung Transplant. 2012;31:1052–1064.
   PubMed Web of Science ®Google Scholar
• Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report–2011. J Heart Lung Transplant. 2011;30:1078–1094.
   PubMed Web of Science ®Google Scholar
• Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol. 2008;52:587–598.
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Page RL, II, Zolty R, et al. Drug therapy in the heart transplant recipient: III, common medical problems. Circulation. 2005;111:113–117.
   PubMed Web of Science ®Google Scholar
• Torres HJ, Merello L, Ramos SA, et al. Prevalence of cardiac allograft vasculopathy assessed with coronary angiography versus coronary vascular ultrasound and virtual histology. Transplant Proc. 2011;43:2318–2321.
   Web of Science ®Google Scholar
• Johnson TH, McDonald K, Nakhleh R, et al. Allograft vasculopathy and death in a cardiac transplant patient with angiographically normal coronary arteries. Cathet Cardiovasc Diagn. 1991;24:37–40.
   Google Scholar
• Braga JR, Santos IS, McDonald M, Shah PS, Ross HJ. Factors associated with the development of cardiac allograft vasculopathy – a systematic review of observational studies. Clin Transplant. 2012;26:E111–E124.
   Web of Science ®Google Scholar
• Lietz K, John R, Mancini DM, Edwards NM. Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list: implications for donor selection criteria. J Am Coll Cardiol. 2004;43:1553–1561.
   Web of Science ®Google Scholar
• Li H, Tanaka K, Anzai H, et al. Influence of pre-existing donor atherosclerosis on the development of cardiac allograft vasculopathy and outcomes in heart transplant recipients. J Am Coll Cardiol. 2006;47:2470–2476.
   Web of Science ®Google Scholar
• Goland S, Czer LS, Kass RM, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol. 2008;51:1214–1220.
   Web of Science ®Google Scholar
• Rockx MA, Haddad H. Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation. Curr Opin Cardiol. 2007;22:128–132.
   Web of Science ®Google Scholar
• Bilchick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal RS. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J. 2004;148:200–210.
   Web of Science ®Google Scholar
• Lu WH, Palatnik K, Fishbein GA, et al. Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant. 2011;30:1044–1050.
   Web of Science ®Google Scholar
• Arora S, Gunther A, Wennerblom B, et al. Systemic markers of inflammation are associated with cardiac allograft vasculopathy and an increased intimal inflammatory component. Am J Transplant. 2010;10:1428–1436.
   Web of Science ®Google Scholar
• Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation. 2008;117:2131–2141.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006;99:801–815.
   PubMed Web of Science ®Google Scholar
• Van Loosdregt J, van Oosterhout MF, Bruggink AH, et al. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation. 2006;114:1599–1607.
   Web of Science ®Google Scholar
• Starnes VA, Stinson EB, Oyer PE, et al. Cardiac transplantation in children and adolescents. Circulation. 1987;76:V43–V47.
   Web of Science ®Google Scholar
• Tuzcu EM, De Franco AC, Goormastic M, et al. Dichotomous pattern of coronary atherosclerosis 1 to 9 years after transplantation: insights from systematic intravascular ultrasound imaging. J Am Coll Cardiol. 1996;27:839–846.
   Web of Science ®Google Scholar
• Khandhar SJ, Yamamoto H, Teuteberg JJ, et al. Optical coherence tomography for characterization of cardiac allograft vasculopathy after heart transplantation (OCTCAV study). J Heart Lung Transplant. 2013;32:596–602.
   Web of Science ®Google Scholar
• Petrakopoulou P, Anthopoulou L, Muscholl M, et al. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression. J Am Coll Cardiol. 2006;47:1622–1629.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011;43:S1–S17.
   PubMed Web of Science ®Google Scholar
• Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58–69.
   PubMed Web of Science ®Google Scholar
• Caforio AL, Tona F, Fortina AB, et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant. 2004;4:962–970.
   PubMed Web of Science ®Google Scholar
• Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11:312–319.
   PubMed Web of Science ®Google Scholar
• Stastny P, Lavingia B, Fixler DE, Yancy CW, Ring WS. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation. 2007;84:738–745.
   Web of Science ®Google Scholar
• Kaczmarek I, Deutsch MA, Kauke T, et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant. 2008;6:229–235.
   PubMed Web of Science ®Google Scholar
• Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005;80:1019–1025.
   PubMed Web of Science ®Google Scholar
• Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant. 2011;30:158–163.
   Web of Science ®Google Scholar
• Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16:12–17.
   PubMed Web of Science ®Google Scholar
• Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol. 2011;72:849–858.
   PubMed Web of Science ®Google Scholar
• Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011;91:342–347.
   PubMed Web of Science ®Google Scholar
• Nath DS, Angaswamy N, Basha HI, et al. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation. Hum Immunol. 2010;71:1191–1196.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Cecka JM, Gjertson DW, et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation. 2011;91:1153–1158.
   PubMed Web of Science ®Google Scholar
• Nath DS, Ilias Basha H, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant. 2010;29:1277–1285.
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant. 1998;17:744–753.
   PubMed Web of Science ®Google Scholar
• Stecker EC, Strelich KR, Chugh SS, Crispell K, McAnulty JH. Arrhythmias after orthotopic heart transplantation. J Card Fail. 2005;11:464–472.
   PubMed Web of Science ®Google Scholar
• Miller CA, Chowdhary S, Ray SG, et al. Role of noninvasive imaging in the diagnosis of cardiac allograft vasculopathy. Circ Cardiovasc Imaging. 2011;4:583–593.
   Web of Science ®Google Scholar
• Prada-Delgado O, Estevez-Loureiro R, Lopez-Sainz A, et al. Percutaneous coronary interventions and bypass surgery in patients with cardiac allograft vasculopathy: a single-center experience. Transplant Proc. 2012;44:2657–2659.
   Web of Science ®Google Scholar
• Mondillo S, Maccherini M, Galderisi M. Usefulness and limitations of transthoracic echocardiography in heart transplantation recipients. Cardiovasc Ultrasound. 2008;6:2–14.
   PubMed Web of Science ®Google Scholar
• Wever-Pinzon O, Romero J, Kelesidis I, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol. 2014;63:1992–2004.
   PubMed Web of Science ®Google Scholar
• Kobashigawa J. Coronary computed tomography angiography: is it time to replace the conventional coronary angiogram in heart transplant patients? J Am Coll Cardiol. 2014;63:2005–2006.
   PubMed Web of Science ®Google Scholar
• Khan R, Jang IK. Evaluation of coronary allograft vasculopathy using multi-detector row computed tomography: a systematic review. Eur J Cardiothorac Surg. 2012;41:415–422.
   Web of Science ®Google Scholar
• Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol. 1988;12:334–340.
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45:1532–1537.
   PubMed Web of Science ®Google Scholar
• Logani S, Saltzman HE, Kurnik P, Eisen HJ, Ledley GS. Clinical utility of intravascular ultrasound in the assessment of coronary allograft vasculopathy: a review. J Interv Cardiol. 2011;24:9–14.
   Web of Science ®Google Scholar
• Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol. 2005;45:1538–1542.
   PubMed Web of Science ®Google Scholar
• Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012;59:1058–1072.
   PubMed Web of Science ®Google Scholar
• Imamura T, Kinugawa K, Murasawa T, et al. Cardiac allograft vasculopathy can be distinguished from donor-transmitted coronary atherosclerosis by optical coherence tomography imaging in a heart transplantation recipient: double layered intimal thickness. Int Heart J. 2014;55:178–180.
   Web of Science ®Google Scholar
• Crespo-Leiro MG, Marzoa-Rivas R, Barge-Caballero E, Paniagua-Martin MJ. Prevention and treatment of coronary artery vasculopathy. Curr Opin Organ Transplant. 2012;17:546–550.
   Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. New Engl J Med. 1995;333:621–627.
   PubMed Web of Science ®Google Scholar
• Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96:1398–1402.
   PubMed Web of Science ®Google Scholar
• Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107:93–97.
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant. 2005;24:1736–1740.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc. 2004;36:1539–1541.
   Web of Science ®Google Scholar
• Erinc K, Yamani MH, Starling RC, et al. The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant. 2005;24:1033–1038.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Kistler KD, Ulsh P, Bergman GE, Vensak J, Morris J. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database. Clin Transplant. 2011;25:E455–E462.
   Web of Science ®Google Scholar
• Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant. 2009;28:461–467.
   PubMed Web of Science ®Google Scholar
• Dasari TW, Hennebry TA, Hanna EB, Saucedo JF. Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature. Catheter Cardiovasc Interv. 2011;77:962–969.
   Web of Science ®Google Scholar
• Vigano M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant. 2007;26:584–592.
   PubMed Web of Science ®Google Scholar
• Topilsky Y, Hasin T, Raichlin E, et al. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation. 2012;125:708–720.
   PubMed Web of Science ®Google Scholar
• Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002;359:1108–1113.
   PubMed Web of Science ®Google Scholar
• Eckl S, Heim C, Abele-Ohl S, et al. Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts. Transpl Int. 2010;23:959–966.
   PubMed Web of Science ®Google Scholar
• Abele S, Weyand M, Wollin M, et al. Clopidogrel reduces the development of transplant arteriosclerosis. J Thorac Cardiovasc Surg. 2006;131:1161–1166.
   Web of Science ®Google Scholar
• Tsai VW, Cooper J, Garan H, et al. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail. 2009;2:197–201.
   Web of Science ®Google Scholar
• Thajudeen A, Stecker EC, Shehata M, et al. Arrhythmias after heart transplantation: mechanisms and management. J Am Heart Assoc. 2012;1:1–8.
   Web of Science ®Google Scholar
• Aqel RA, Wells BJ, Hage FG, et al. Re-stenosis after drug-eluting stents in cardiac allograft vasculopathy. J Heart Lung Transplant. 2008;27:610–615.
   Web of Science ®Google Scholar
• Agarwal S, Parashar A, Kapadia SR, et al. Long-term mortality after cardiac allograft vasculopathy: implications of percutaneous intervention. JACC Heart Fail. 2014;2:281–288.
   PubMed Web of Science ®Google Scholar
• Tjang YS, Tenderich G, Hornik L, et al. Cardiac retransplantation in adults: an evidence-based systematic review. Thorac Cardiovasc Surg. 2008;56:323–327.
   Web of Science ®Google Scholar
• Tsao L, Uriel N, Leitz K, et al. Higher rate of comorbidities after cardiac retransplantation contributes to decreased survival. J Heart Lung Transplant. 2009;28:1072–1074.
   Web of Science ®Google Scholar
• Arbustini E, Roberts WC. Morphologic observations in the epicardial coronary arteries and their surroundings late after cardiac transplantation (allograft vascular disease). Am J Cardiol. 1996;78(7):814–820.
   Web of Science ®Google Scholar